Focus Partners Wealth
LBRX icon

Focus Partners Wealth’s LB Pharmaceuticals LBRX Stock Holding History

Focus Partners Wealth’s Portfolio LBRX Stock Details LBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$635K Sell
19,573
-242
-1% -$7.11K ﹤0.01% 1845
2026
Q1 		$489K Sell
19,815
-280
-1% -$6.46K ﹤0.01% 1944
2025
Q4 		$447K Buy
+20,095
New +$351K ﹤0.01% 2003

Other funds holding LBRX

Deep Track Capital
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Trails Edge Capital Partners
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Commodore Capital
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
TCG Crossover Management
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Caligan Partners
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Nantahala Capital Management
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Focus Partners Wealth's LBRX Position: Q2 2026 in Review

Focus Partners Wealth reduced its LB Pharmaceuticals (LBRX) stake by 1.2% in Q2 2026, selling an estimated $7.11K and leaving 19,573 shares worth $635K. The position accounts for ﹤0.01% of the portfolio, ranked #1845.

Focus Partners Wealth first reported a position in LBRX in Q4 2025 and has held it in 3 quarters since. 114 funds tracked by Wall St. Rank hold LBRX as of Q2 2026.

  • Focus Partners Wealth held 19,573 shares of LB Pharmaceuticals worth $635K as of Q2 2026.
  • Focus Partners Wealth sold 242 LB Pharmaceuticals shares in Q2 2026, an estimated $7.11K.
  • LB Pharmaceuticals made up ﹤0.01% of Focus Partners Wealth's portfolio in Q2 2026, its #1845 holding.
  • Focus Partners Wealth first reported a position in LB Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 114 funds tracked by Wall St. Rank held LB Pharmaceuticals as of Q2 2026.

Based on Focus Partners Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.